Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) EBITDA Margin (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed EBITDA Margin for 8 consecutive years, with 2030.75% as the latest value for Q2 2025.

  • Quarterly EBITDA Margin changed N/A to 2030.75% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 13158.7% through Dec 2025, changed N/A year-over-year, with the annual reading at 1419.61% for FY2025, N/A changed from the prior year.
  • EBITDA Margin for Q2 2025 was 2030.75% at Crescent Biopharma, up from 17804.21% in the prior quarter.
  • The five-year high for EBITDA Margin was 2030.75% in Q2 2025, with the low at 10144001.41% in Q2 2021.
  • Average EBITDA Margin over 3 years is 1713337.81%, with a median of 18916.51% recorded in 2021.
  • The sharpest move saw EBITDA Margin tumbled -8931525bps in 2021, then skyrocketed 1012619720bps in 2022.
  • Over 3 years, EBITDA Margin stood at 98870.2% in 2021, then surged by 82bps to 17804.21% in 2022, then skyrocketed by 111bps to 2030.75% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 2030.75%, 17804.21%, and 98870.2% for Q2 2025, Q2 2022, and Q4 2021 respectively.